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Abstract
Background: The synthesis of specific, potent progesterone antagonists adds potential agents to the breast cancer
prevention and treatment armamentarium. The identification of individuals who will benefit from these agents will
be a critical factor for their clinical success.
Methods: We utilized telapristone acetate (TPA; CDB-4124) to understand the effects of progesterone receptor (PR)
blockade on proliferation, apoptosis, promoter binding, cell cycle progression, and gene expression. We then
identified a set of genes that overlap with human breast luteal-phase expressed genes and signify progesterone
activity in both normal breast cells and breast cancer cell lines.
Results: TPA administration to T47D cells results in a 30 % decrease in cell number at 24 h, which is maintained
over 72 h only in the presence of estradiol. Blockade of progesterone signaling by TPA for 24 h results in fewer cells
in G2/M, attributable to decreased expression of genes that facilitate the G2/M transition. Gene expression data
suggest that TPA affects several mechanisms that progesterone utilizes to control gene expression, including
specific post-translational modifications, and nucleosomal organization and higher order chromatin structure, which
regulate access of PR to its DNA binding sites.
Conclusions: By comparing genes induced by the progestin R5020 in T47D cells with those increased in the
luteal-phase normal breast, we have identified a set of genes that predict functional progesterone signaling in
tissue. These data will facilitate an understanding of the ways in which drugs such as TPA may be utilized for the
prevention, and possibly the therapy, of human breast cancer.
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Background
Endocrine agents are a mainstay of therapy for hormone
receptor positive breast cancer. Pharmacologic antago-
nists targeting both estrogen and progesterone activity
were developed in the 1960s [1]. In the ensuing half-
century, selective estrogen receptor (ER) modulators
(SERMs) and Aromatase Inhibitors (AIs) have had un-
equivocal success in the treatment and prevention of
breast cancer [2–4]. The antiprogestin onapristone (ZK
98.299) showed preclinical and clinical efficacy but trial
recruitment was halted secondary to significant liver
toxicity largely attributable to binding to other nuclear
receptors, most notably glucocorticoid receptor (GR)
[5, 6]. Consequently, the strategy of blocking progesterone
receptor (PR) activity to prevent and treat breast cancer
was largely abandoned. However, there is compelling evi-
dence to suggest that blocking PR signaling may have sig-
nificant clinical utility. Data from the Women’s Health
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Initiative and the Million Woman Study clearly show that
exposure to medroxyprogesterone acetate (MPA), a pro-
gestin, is a risk factor for the development of breast cancer
[7, 8]. Progesterone may promote oncogenic progression
by stimulating the proliferation that occurs during the
menstrual cycle [9], by reanimating stem cells [10], or by
driving the proliferation of early, i.e. occult, lesions [5].
The recent availability of relatively potent progesterone
antagonists with little to no antiglucocorticoid activity,
such as telapristone acetate (TPA; CDB-4124) [11, 12]
prompts renewed interest in the anti-cancer effects of
these agents. Competitive binding assays show that while
TPA retains much of the antiprogesterone activity of mife-
pristone (RU-486), the antiglucocorticoid potency of TPA
and its metabolites is less than 4 % that of mifepristone
[11]. In an ongoing Phase II pre-surgical window trial, we
are testing the anti-proliferative efficacy of TPA in early
stage breast cancer (clinicaltrials.gov NCT01800422). In
the present report, we have employed TPA as a tool to
probe the actions of a variety of progestogens (progester-
one, MPA, and R5020) in breast cancer cell lines. R5020
(promegestone) is a 19-norprogesterone derivative with a
higher binding affinity for PR and a slower dissociation
rate from the receptor-ligand complex when compared to
progesterone [13, 14]. Additionally, we sought to identify
a set of genes that signify progesterone activity or block-
ade. Our goal is to use these genes or combinations as bio-
markers indicating successful abrogation of progesterone
signaling in early phase trials that will test the utility of
antiprogesterone therapy.
Methods
Cell culture and chemicals
T47D, BT474 and MCF-7 breast cancer cell lines were
obtained from Dr. Charles V. Clevenger (Department of
Pathology, Virginia Commonwealth University, Rich-
mond, VA, USA) and MCF10A immortalized normal
mammary epithelial cells were purchased from The
American Type Culture Collection (ATCC, Manassas,
VA, USA). T47D, BT474 and MCF-7 are ER+/PR+ cell
lines; T47D has the highest PR expression of the three
cell lines [15]. T47D, BT474 and MCF-7 cells were
maintained in phenol free MEM supplemented with
10 % FBS (Atlanta Biologicals, Norcross, GA, USA),
2 mM L-glutamine, 1 % MEM-NEAA, 0.075 % Sodium
bicarbonate and 100 units/mL of penicillin, 100 μg/mL
of streptomycin and 25 μg/mL of Fungizone® in a hu-
midified incubator at 37 °C and 5 % CO2. MCF10A cells
were grown in DMEM/F12 containing 5 % horse
serum, 20 ng/mL EGF, 0.5 mg/mL hydrocortisone (Sigma-
Aldrich, St. Louis, MO, USA), 100 ng/mL cholera toxin
(Sigma-Aldrich, St. Louis, MO, USA), 10 μg/mL insulin,
and 100 units/mL of penicillin, 100 μg/mL of strepto-
mycin, and 25 μg/mL of Fungizone®. Cell growth media
and all of the cell culture supplements were purchased
from Gibco® (Carlsbad, CA, USA) unless indicated. Estra-
diol (E2), progesterone (P4), 17α-hydroxy-6α-methylpro-
gesterone acetate (MPA) and Mifepristone (RU486) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Pro-
megestone (R5020) was obtained from PerkinElmer (Santa
Clara, CA, USA). 17α-acetoxy-21 methoxy-11β[4-N,N-
dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione
(telapristone acetate, TPA; CDB4124) was provided by Re-
pros Therapeutics (The Woodlands, TX, USA). E2, and
progestogens (P4, MPA and R5020) were reconstituted in
ethanol and TPA in DMSO. All solvents were cell culture
grade and the working solutions were stored at −20 °C.
Cell viability assay
The viability of T47D cells was evaluated by MTT assay
according to the manufacturer’s instructions (Roche Life
Science, Indianapolis, IN, USA). 5,000–10,000 cells were
plated per well of a 96-well plate in 200 μL of growth
media supplemented with 5 % charcoal-stripped FBS
(CHS/FBS, Atlanta Biologicals, Norcross, GA, USA) and
incubated for 24 h. These hormone-starved cells were then
treated with 10 nM P4, 10 nM MPA, 10 nM R5020 ± TPA
(0.1 μM, 1 μM) alone or in combination with 1 nM E2.
Control cells received ethanol. Cell viability at 24, 48 and
72 h was determined by measuring metabolic activity of
living cells as relative colorimetric changes. All experi-
ments were repeated at least three times. Two-way ana-
lysis of variance (ANOVA) was used to determine the
significant differences between treatments. The Bonferroni
test was used to analyze multiple comparisons. All statis-
tical tests were performed using GraphPad Prism (Graph-
Pad Software, La Jolla, CA, USA).
Proliferation and apoptosis
Apoptosis and Cell proliferation were examined using
Annexin V (Molecular Probes, Thermo Fisher Scientific,
Waltham, MA, USA, Cat# A23204) and Ki-67 (BD
Biosciences, San Jose, CA, USA, cat# 561126) labeling re-
spectively. T-47D cells were cultured in regular media as
described above. At 80–85 % cell confluence, the cell cycle
was synchronized by serum starvation. Following that,
treatment with vehicle, R5020 (10nM), and R5020 with
TPA (1 μM) for 0 h, 24 h, 48 h, and 72 h in 5 % charcoal
stripped FBS, phenol red free MEM (Atlanta Biologicals,
Norcross, GA, USA) was performed. The treated cells
were then disassociated, counted, aliquoted in two sets
and incubated with Annexin V or Ki-67 as per manufac-
turer’s recommendations. Cell cycle was analyzed using
BD LSRFortessa flow cytometer (BD Biosciences, San Jose,
CA, USA) and data analysis was performed using Graph-
pad Prism Ver 6.0 (San Diego, CA, USA). Two-way
ANOVA was utilized to determine the significance of the
differences over the time course of the experiments and
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Tukey’s test to determine significance between treatments
at individual time points.
Immunoblotting
3 × 105 cells of T47D and BT474 were hormone-starved
for 24 h. T47D cells were then treated with 10 nM
R5020 for 24 h. BT474 cells were incubated with 1 nM
E2 for 72 h, washed twice with growth media, and
treated with 10 nM R5020 for 24 h. Cells were harvested
and whole proteins extracted in RIPA buffer (Pierce,
Rockford, IL, USA) including protease inhibitor cocktail
and EDTA. Protein concentration was determined using
the BCA Protein Assay Kit (Pierce, Rockford, IL, USA)
and identical amounts of protein were separated in 10 %
NuPAGE Bis-Tris SDS/PAGE Protein Gels (Invitrogen,
Carlsbad, CA, USA) followed by transfer onto a polyvi-
nylidene difluoride membrane (Invitrogen, Carlsbad,
CA, USA). The membrane was probed with anti-PR
antibodies (Santa Cruz Biotechnology, Paso Robles, CA,
USA) followed by incubation with a secondary goat anti-
mouse antibody (Pierce, Rockford, IL, USA). The blots
were developed using the ECL Prime Western Blotting
Detection Reagent (Amersham, Piscataway, NJ, USA).
Anti-GAPDH antibodies (Santa Cruz Biotechnology,
Paso Robles, CA, USA) were used for loading controls
of proteins.
Cell cycle analysis
Cell cycle distribution was examined by measuring the
cellular DNA content using propidium iodide (PI) and
flow cytometry. T47D cells, growing in the exponential
phase were hormone-starved for 24 h in growth media
containing 5 % CHS/FBS; and BT474 cells, after 72 h ex-
posure to E2, were treated with 10 nM P4, 10 nM MPA,
10 nM R5020 ± TPA (0.1 μM, 1 μM) alone or in combin-
ation with 1 nM E2 for 24 h. After incubation, cell pel-
lets were collected by centrifugation, washed twice
with PBS, fixed in 70 % (v/v) ice-cold ethanol for
24 h at −20 °C and then stained with PI (50 μg/mL)
containing RNase (100 μg/mL) and 0.1 % Triton X-
100 for 30 min in the dark at 37 °C. Cell cycle was
analyzed using BD LSRFortessa flow cytometer (BD Bio-
sciences, San Jose, CA, USA) and FlowJo vX (FlowJo, LLC,
Ashland, OR, USA).
Measurement of PRE promoter activity
The PRE-luciferase reporter plasmid was a generous gift
from Dr. Dean P. Edwards (Baylor College of Medicine,
TX). T47D, BT474 and MCF-7 cells (1.2 × 105 cells)
were plated in a 24-well plate and hormone-starved
for 24 h. Cells were then transfected with 0.8 μg of
PRE-luc reporter plasmid along with phRl-TK
(0.01 μg) Renilla control plasmid using Lipofectamine
2000 (Life technologies, Carlsbad, CA, USA)
according to the manufacturer’s instructions. The
transfected T47D cells were treated with 10 nM P4,
10 nM MPA, 10 nM R5020 ± TPA (10 nM, 100 nM,
1 μM) alone or in combination with 1nM E2. Control
cells received ethanol and DMSO as vehicle. Cells
were processed and the luminescence from firefly and
Renilla luciferase was measured using the Dual-
Luciferase® Reporter Assay System (Promega, Madi-
son, WI, USA) and the Synergy HT microplate reader
(BioTek, Winooski, VT, USA). The relative PRE- lu-
ciferase activity was expressed as the ratio of the fire-
fly luciferase/Renilla luciferase unit (RLU).
Microarray analysis and statistical analysis
Three separate T47D cell cultures were used for micro-
array analysis. The experimental treatments were vehicle,
10 nM R5020, 1 μM TPA, and 10 nM R5020 with 1 μM
TPA. All RNA samples were processed at the Genomics
Core Facility in the Center for Genetic Medicine at North-
western University (Chicago, IL). The quality of total RNA
was evaluated using the Bioanalyzer 2100 (Agilent Tech-
nologies, Inc., Santa Clara, CA, USA). 150 ng of each
RNA sample, with 260/280 and 28S/18S ratio of greater
than 1.8, was used to make double-stranded cDNA. Gene
expression analysis was performed using the Illumina Hu-
man HT-12v4 Expression BeadChip. Quality checks and
probe level processing of the Illumina microarray data
were further made with the R Bioconductor package lumi
(http://www.bioconductor.org/packages/release/bioc/html/
lumi.html). Data was quantile normalized, and hierarchical
clustering and Principal Component Analysis were per-
formed on the normalized signal data to assess the sample
relationship and variability. Probes absent in all samples
were filtered out according to Illumina’s detection p-values
in the downstream analysis. Differential gene expression
between the different conditions was assessed by a statis-
tical linear model analysis using the bioconductor package
limma (http://www.bioconductor.org/packages/release/bioc
/html/limma.html). The moderated t-statistic p-values de-
rived from the limma analysis above were further adjusted
for multiple testing by Benjamini and Hochberg’s method
to control false discovery rate (FDR) [16]. The lists of differ-
entially expressed genes were obtained by the FDR criteria
of <5 % and fold change cutoff of > ± 1.5. Data obtained
from the microarray was further analyzed by MetaCore
(Thompson Reuters; https://portal.genego.com) and In-
genuity Pathway Analysis (IPA; Qiagen, http://www.inge
nuity.com).
Validation of gene expression for selected 16 genes
Cell cycle regulating genes responding to both R5020
and TPA (microarray data) were compared with cell
cycle genes upregulated by progesterone in luteal phase
of normal breast tissue (RNA-Seq data) [17] and 16
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genes that were significantly differentially expressed
were identified. The expression of these 16 genes was
validated with reverse transcription-quantitative poly-
merase chain reaction (RT-qPCR). Briefly, RNA from
the gene arrays was reverse transcribed into cDNA
using the SuperScript VILO cDNA Synthesis Kit (Life
technologies, Carlsbad, CA, USA). Real-time qPCR
was performed using an ABI PRISM 7900 Sequence
Detection System (Applied Biosystems, Life technolo-
gies, Carlsbad, CA, USA). The geometric mean of
housekeeping gene (GAPDH and β-Actin) was used
as an internal control to normalize the variability in
expression levels. PCR primers used for real-time
PCR were purchased from integrated DNA technolo-
gies (Coralville, IA, USA) and the list of the primers
is provided in Additional file 1: Table S4. Expression
data of the 16 genes was normalized to housekeeping
genes GAPDH and β-Actin to control the variability in ex-
pression levels and were analyzed using the 2-ΔΔCT
method described by Livak and Schmittgen [18]. The
expression of the 16 genes was validated by real-time
PCR using T47D and MCF10A cells. 6.0 × 105 cells
of T47D and MCF10A were hormone-starved for
24 h. Cells were then treated with 10 nM P4, 10 nM
MPA, 10 nM R5020 ± TPA for 24 h. Vehicle treated
cells were used as a control. Total RNA from samples
was extracted using Trizol reagent (Life technologies,
Carlsbad, CA, USA). 2 μg of total RNA was con-
verted to cDNA using SuperScriptVILO master mix
(Life technologies, Carlsbad, CA, USA) according to
the manufacturer’s instruction. Real-time PCR and
data analysis were as above. Two-way analysis of vari-
ance (ANOVA) was used to determine the significant
differences between treatments. The Sidak correction
was applied to analyze multiple comparisons. All stat-
istical tests were performed using GraphPad Prism
(GraphPad Software, La Jolla, CA, USA).
Regulation of expression of the selected 16 genes
Motif analysis was performed using HOMER (v4.8) to
identify common sequences in the promoters among the
16 genes of interest (Salk Institute, La Jolla, CA, USA;
http://homer.salk.edu/homer/). The ENCODE transcrip-
tion factor (TF) binding site tracks were enabled for the
MCF-7 cell line to determine if promoters of the se-
lected 16 genes are bound by the same TFs (https://
www.genome.ucsc.edu/ENCODE/).
Results
Effect of progestogens and TPA on cell number
The proliferation of T47D cells was assayed in the pres-
ence of progestogens alone (P4, MPA and R5020) at 24,
48 and 72 h. There was significant stimulation of prolif-
eration by all progestogens at 24 h as shown in Fig. 1a-c
(Additional file 2: Table S1). Proliferation at 24 h was
2.1-fold greater in the presence of P4, and 3-fold greater
in the presence of MPA (Fig. 1b) and R5020 (Fig. 1c)
than with vehicle treatment. The proliferation of the
MPA and R5020 cultures plateaus between 24 and 48 h;
proliferation resumes between 48 and 72 h (Fig. 1b-c).
The plateau is well known phenomenon in the setting of
continuous progestogens and is due to arrest in late G1
consequent to increased levels of p21 and p27kip, and
decreased levels of Cyclins A, B and D [19]. The in-
creased formazan observed at 24 h in the presence of
progestogens was blocked by the addition of the anti-
progestin TPA; up to 30 % inhibition was produced by
both low (0.1 μM) and high (1.0 μM) concentrations of
the inhibitor (p < 0.001).
At 24 h, proliferation stimulated by E2 alone was less
when compared to P4 alone (Fig. 1g and a); the combin-
ation of E2 with the progestogens mimicked the prolifer-
ation curves of the progestogens alone and there did not
appear to be an additive or synergistic effect. However,
at 72 h, proliferation in the presence of E2 alone (Fig. 1g)
was 28–35 % greater than that of E2 plus the progesto-
gens (p < 0.0001; Fig. 1d-f ). The addition of TPA to E2
plus progestogen cultures resulted in 22–37 % inhibition
of formazan production in comparison to E2 plus pro-
gestogens (p < 0.0001; Fig. 1d-f ). The incremental de-
crease in formazan at 72 h, E2 vs. E2 + R5020 vs. E2 +
R5020 + TPA, is observed best in 1 F. As judged from
Fig. 1a-f, it appears that the major effect of TPA occurs
in the first 24 h; after this time point the slopes of the
lines between 24–48 h and 48–72 h are quite similar
when E2 is present (Additional file 1: Table S2); the lines
converge at 72 h when E2 is not present. Thus the effect
TPA in T47D cells is more persistent in the presence of
E2 + progestogens, than with progestogens alone (Figs
A-C compared to D-F). To complete the picture, forma-
zan production was measured in the presence of E2 and
TPA but without progestogens. As shown in Fig. 1g, a
dose dependent decrease occurs at both 48 (0.1 μM:
27 %; 1 μM: 43 %) and 72 h (0.1 μM: 29 %; 1 μM: 48 %),
p < 0.0001 [20, 21]. Overall, the proliferation of T47D
cells is most significant within the first 24 h after expos-
ure to PR ligands alone or in the presence of E2, which
is diminished by the addition of TPA at both high and
low dose.
Effect of progestogens and TPA apoptosis and
proliferation
T47D cells cultured in the presence of R5020 [10nM]
and TPA [1.0 μM] demonstrate a significant increase in
apoptosis at 24 h (p < 0.05), which then decreases and is
not different from to that of vehicle and R5020 at 48
and 72 h (Fig. 2a). Proliferation, as measured by Ki67,
increased steadily and at a similar rate over the time
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Fig. 1 Determination of cell viability by MTT assay. T47D cells were hormone-starved for 24 h and treated for 24, 48, and 72 h with (a) P4 ± TPA,
(b) MPA ± TPA, (c) R5020 ± TPA alone, or in combination with E2 (d, e, and f). Cells were also treated with E2 ± TPA (g). Vehicle treated cells were
used as a control. X-axis: 24, 48, and 72 h time points. p-values for the various comparisons are provided in Additional file 2: Table S1
Fig. 2 Annexin V and Ki67 expression analysis by flow cytometry. T47D cells were serum-starved for 24 h and treated with R5020 ± TPA for 24, 48
and 72 h. The percent of cells expressing each of the proteins was determined using flow cytometry. a. Annexin V. b. Ki67. Vehicle-treated cells
were used as a control. * represents p value <0.05. h = hours
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course of the experiment in the presence of R5020
(Fig. 2b). The addition of TPA significantly decreased
the percent of proliferating cells at 24 h (p < 0.05) and
this percentage remained largely unchanged at the latter
two time points.
Effects of progestogens and TPA on the cell cycle
Since majority of stimulation of proliferation of T47D
occurs within the first 24 h after treatment with proges-
togens (P4, MPA and R5020) and this stimulation is
blocked by TPA, the 24-h time point became the focus
of further studies. Cell cycle analysis was performed after
treatment of the cells with the progestogens ± TPA. As
shown in Fig. 3a-c, P4, MPA and R5020 decreased the
fraction of cells in G0/G1 and increased the fraction in
G2/M and, to a lesser extent, S phase, when compared
to vehicle at 24 h. The addition of TPA at both low and
high doses (0.1 μM and 1 μM) resulted in increased
numbers of cells in G0/G1 and decreased S and G2/M
fractions (Fig. 3a-c). The addition of E2 alone resulted in
fewer cells in G0/G1 and an increase in the fraction of
cells in S and G2/M (Fig. 3d-f). Addition of TPA to E2 +
P4 and E2 + R5020, at both low and high doses, produced
an increase of cells in G0/G1 (Fig. 3d,f); however, low dose
TPA did not affect cell cycle progression in E2 +MPA
treated cells. Similarly, as shown in Fig. 3d-f, the percent-
ages of cells in S and G2/M were decreased in the pres-
ence of both low and high dose TPA with E2 and P4 or
Fig. 3 Cell cycle analysis by flow cytometry. T47D cells were hormone-starved for 24 h and treated with progestogens (P4, MPA, R5020) ± TPA (a,
b, and c) and in combination with E2 (d, e, and f) for 24 h. The fraction of cells in G1, S and G2/M phase was determined by flow cytometry
using Propidium iodide. Vehicle-treated cells were used as a control
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R5020 but MPA showed no significant changes at the low
dose of TPA.
The above experiment was repeated in a second cell
line: BT474. In comparison to T47D, BT474 cells ex-
press less PR [15] and the response to R5020 was
somewhat attenuated (Fig. 4a,b). Therefore, the
BT474 cells were incubated with E2 for 72 h to in-
crease PR expression (Fig. 4c) prior to treatment with
progestogens and TPA. As shown in Fig. 4d, R5020
decreased the fraction of cells in G0/G1 and, in dis-
tinction to T47D (Fig. 4a), increased the fraction in S
and, to a lesser extent, G2/M when compared to ve-
hicle at 24 h. The addition of TPA to R5020 treat-
ment resulted in increased G0/G1 and decreased S
and G2/M fractions when compared to R5020 alone.
In both T47D and BT474 cells, the addition of E2 to
R5020 had no marked effect on the distribution of
cells within the cell cycle compared to R5020 alone.
Combining TPA with E2 and R5020 abrogated the ef-
fects on cell cycle progression in both cell lines.
TPA blocks PRE reporter activity
Upon treatment with P4, MPA and R5020, PRE reporter
activity increased significantly, which was further en-
hanced by the addition of E2 (Fig. 5a-c). T47D cells exhib-
ited significantly higher induction of PRE, in comparison
to MCF-7 (Fig. 5d) and BT474 (Fig. 5e). Increasing doses
of TPA decreased the progestin-driven PRE reporter activ-
ity in a dose dependent manner. TPA effectively blocked
P4-driven reporter activity at 10nM whereas R5020 and
MPA driven reporter required 100nM for complete inhib-
ition of activity. Similarly, TPA led to dose dependent in-
hibition of PRE induction in MCF7 or BT474 as shown in
Fig. 5d and e, respectively. In summary, these data suggest
TPA disrupts the recruitment or binding of ligand-bound
PR at the PRE within the promoter region of progesterone-
regulated genes.
Identification of progestin-driven genes inhibited by TPA
T47D cells were treated with 10nM R5020 for 24 h;
vehicle-treated cells were used as control. A total of 686
Fig. 4 Cell cycle of T47D cells and BT474 cells after treatment with R5020 [10nM] or E2 [1nM] + R5020 [10nM] alone or in presence of TPA [1 μM].
a. T47D and b. BT474 cells were serum-starved for 24 h and subsequently treated with E2, R5020 and the antiprogestin TPA in various
combination as indicated in figure for 24 h. Cell cycle analysis was performed in presence of Propidium Iodide to measure G1, S and G2/M
fractions. c. Immunoblot of increased PR expression after 72 h of exposure of BT474 cells to E2 (left) and after 24 h of exposure to R5020 (right).
E2 significantly increase both PR-A and B protein expression. The loss of PR expression with exposure to R5020 is indicative of high transcriptional
activity and rapid protein turnover [44]. The blot has been cropped to remove the 48 h data. d. *BT474 cells were stimulated with E2 [1nM] for
72 h prior to treatment of R5020 and TPA to increase PR expression
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genes were differentially expressed in presence of 10 nM
R5020 (adjusted p value <0.001; Additional file 1: Table S2).
Addition of TPA resulted in 790 genes that were differen-
tially expressed compared to R5020 alone. Within these
two gene sets there was an overlap of 589 genes, in that
genes evincing increased expression with R5020 (≥1.5x)
were decreased (≤1.5x) by the addition of TPA (Fig. 6b).
The expression data was analyzed using MetaCore Gene
Go (Thompson Reuters). Pathway enrichment analysis re-
vealed that the pathways upregulated by the progestin
R5020 are the same pathways downregulated by the
addition of the antiprogestin TPA (Fig. 6c). These pathways
are involved in the regulation of functions that occur during
the cell cycle. The most significantly enriched cell processes
are shown in Fig. 6d. In concert with the pathway data, the
biologic process data revealed enrichment for mitosis, cyto-
kinesis processes, organelle duplication and the cell cycle.
There were only six genes differentially expressed in
the comparison of T47D cells treated with TPA alone
versus control (data not shown).
Progesterone receptor signaling and the G2/M phase of
cell cycle
In order to cull the hundreds of differentially expressed
genes for the purpose of identifying a set of genes that
predicts functional progesterone signaling in human
breast tissue, and to increase relevance to the prevention
arena, genes regulated by R5020, as determined by the
microarray (Additional file 1: Table S3), were compared
with the genes which were significantly increased during
the luteal (progesterone rich) phase in our RNA-Seq
study [17]; 16 genes common to both gene sets were se-
lected (Fig. 6b). Of note, the menstrual phase determina-
tions in the RNA-Seq study were based on both menstrual
Fig. 5 PRE promoter activity analysis by Dual luciferase assay. T47D, BT474, and MCF-7 cells were hormone-starved for 24 h and transfected with
PRE-luc reporter plasmid along with phRl-TK Renilla control plasmid. The transfected T47D cells were treated with P4 (a), MPA (b), or R5020
(c) ± TPA (10nM, 100nM, 1 μM) alone or in combination with E2 (1nM). The transfected MCF-7 (d) and BT474 cells (e) received P4 or MPA ± TPA
(10nM, 100nM, 1 μM). Luciferase activity was quantified using the Dual- Luciferase Reporter Assay Kit. The relative PRE- luciferase activity was
expressed as the ratio of the firefly luciferase/Renilla luciferase unit (RLU)
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dates and serum hormone concentrations. This strategy en-
sured that we were focusing on genes that are expressed in
the normal breast consequent to progesterone stimulation.
The majority of the 16 genes that emerged from this com-
parison are expressed during the G2/M phase of cell cycle.
Additional analysis of the microarray data showed that the
expression of the sixteen genes was significantly decreased,
relative fold change <1.5 with adjusted p value <0.001
(Additional file 1: Table S3), by the addition of TPA to
R5020. Technical validation (Additional file 3: Figure S1)
was done by RT-qPCR using RNA from the microarray,
which revealed significant upregulation of 13 genes by
R5020 and an inhibition of this induction with TPA. Fur-
thermore, this 16-gene panel was validated in an independ-
ent set of experiments (biologic validation) treating T47D
or MCF10A cells with the three progestogens with or with-
out TPA, using RT-qPCR (Fig 7). While all 16 genes evi-
denced increased expression in the presence of P4, R5020,
and MPA, the levels of induction varied depending on the
progestogens used. R5020 increased expression of the 16
genes, as did P4, however the induction was not as robust
with MPA. TPA decreased expression of these genes
regardless of the progestogens used. Topoisomerase 2A
was an outlier in that its expression increased in the pres-
ence of R5020 and R5020 +TPA. MCF10A cells, which lack
the expression of both ER and PR, demonstrated little to
no response to the progestogens and TPA.
Regulation of the expression of the 16 genes
Motif analysis 400 bp upstream of the transcription start
site (TSS) and 100 downstream revealed the presence of
the CHR motif for 11 of the 16 genes (Additional file 4:
Tables S7 & S8). Likewise, the NFY motif was present in
14 of the 16 genes (Additional file 4: Tables S7 & S9).
The MMB (Myb-MuvB) complex and FOXM1 have
been demonstrated to bind to the conserved CHR elem-
ent in 11 of the 16 genes (Additional file 4: Table S10)
[22]. Ingenuity Pathway Analysis Upstream Analysis of
the R5020 versus R5020 + TPA differentially expressed
gene data displays inhibition of genes that are tran-
scribed in response to the transcription factors PGR,
FOXM1 and MYC (Additional file 4: Table S5). This
analysis also predicted that NFYA and MYBL2 are inhib-
ited in the presence of TPA although their differential
Fig. 6 Analysis of gene expression microarray. T47D cells were treated with R5020 (10nM) ± TPA (1 μM) for 24 h. Vehicle treated cells were used
as a control. Differential gene expression was assayed using the Illumina platform. (a) Heatmap of 589 genes commonly regulated by R5020 and
TPA. (b) Identification of 16 cell cycle genes upregulated by progesterone both in normal and breast cancer cells. (c) Top ten enriched pathways
for control vs. R5020 and R5020 vs. R5020 + TPA analyzed by GO. (d) Top ten enriched cell processes for control vs. R5020 and R5020
vs. R5020 + TPA
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expression did not meet our cut off of ± 1.5x. The
SMARCE1 transcription factor was predicted to be acti-
vated. The TFs assayed as binding MCF-7 in the EN-
CODE data sets are relatively few. There was robust
E2F1 binding of the majority of the 16 genes and MYC
binding 11 of the 16 (Additional file 4: Table S6).
Specific gene expression changes with mechanistic
implications for TPA’s effects
EGFR and p21 expression were downregulated by TPA,
−1.40 and −2.61-fold respectively. A number of genes
that encode proteins involved in chromatin remodeling
have altered expression following the administration of
TPA including MSK1 (−1.67-fold), SMARCE1 (1.63-
fold), and BAF57 (+1.63-fold).
Discussion
We have described, for the first time, the molecular con-
sequences of blocking progesterone signaling in PR posi-
tive breast cancer cells using a potent PR antagonist,
TPA. Our major findings include the observation that
blockade of progesterone signaling by TPA results in a
decreased G2/M fraction, caused by decreased expres-
sion of genes that facilitate the G2/M transition. This ef-
fect is observed with P4 and R5020 and to a lesser
extent with MPA. The addition of E2 to progestogens
(P4, R5020, and MPA) results in somewhat greater in-
crease in proliferation and more marked inhibition by
TPA. In the absence of E2 (Fig. 1a-c) T47D proliferation
at 72 h is unaffected by the presence of TPA. Progestin
treatment of T47D cells leads to the rapid degradation
of PR in the 26S proteasome [23], which suggests that
the lack of drug effect in the absence of E2 may be due
to the lack of a target. Pretreatment ER+/PR+ breast
cells lines with estrogen for 72 h prior to the administra-
tion of a progestin had been shown to increase PR occu-
pancy on DNA consequent to the increase in steady
state levels of PR and the sites occupied are, to a great
extent, the canonical PR binding sites [24]. The data
from the E2 pretreated BT474 cells (Fig. 4d) contributes
corroborating evidence that E2 driven expression of PR
provides the target for the antiprogestin. The fact that
the anti-proliferative efficacy of TPA requires the pres-
ence of E2 and P4 is highly relevant to the human condi-
tion, since humans are not exposed naturally to
progestogens alone. TPA competes with progestogens
for PR binding [11]. The PRE reporter experiments sug-
gest that both MPA and R5020 have greater binding af-
finity for the receptor than P4 as it takes an order of
magnitude greater concentration of TPA to have the
same effect.
Groshong et al. studied the effect of R5020 ±mifepris-
tone on T47D cells that are PR negative or contain one
of the two PR isoforms [19]. With regard to cell cycle
distribution, their data suggest that, for the most part,
antiprogestins block the transient increase in mitogenic
activity, i.e., the increase in S + G2/M, which peaks ap-
proximately 20–24 h after in the addition of the
Fig. 7 RT-qPCR validation of array data. RT- qPCR data for the sixteen genes show is displayed as a heat map (low to high: yellow to red) with
fold-change in mRNA expression within the boxes. Hormone-starved T47D and MCF10A cells were treated for 24 h with Progesterone (P4),
Medroxyprogesterone acetate (MPA), or Promegestol (R5020) alone or in combination with telapristone actetate (TPA) as indicated above the
map. There were six independent repeats of the experiment. */**/*** represent p-values of < 0.5/<0.01/<0.001, respectively, for R5020 vs. vehicle;
and #/##/### represent p-values of <0.5/<0.01/<0.001 for R5020 vs. R5020 + TPA
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progestogen. For the PR-B isoform, there is no change in
the G0/G1 fraction in the presence of mifepristone when
compared to control arguing against an increase in qui-
escent, G0, cells; for the PR-A isoform there is an in-
crease in this fraction. This is quite similar to what was
observed for TPA: The majority of the effect on cell
cycle distribution is due to the elimination of the in-
crease in the S + G2/M fraction observed in the presence
of progestogen alone but an increase in number of cells
in G0 (Fig. 2) also probably contributes to a small in-
crease in the G0/G1 fraction.
Our data add to the body of knowledge of progestogen
signaling by providing a detailed view of the effects of lon-
ger, i.e., 24 h, exposure to R5020. Previously published
data reflects exposure of T47D cells to R5020 for 6 h [18]
and 12 h [25]. Many of the genes upregulated at 6 h are
those associated with the rapid signaling via the cytoplas-
mic kinases, a process initiated by growth factor binding
to its receptor with consequent regulation of the G1/S
transition of the cell cycle (Additional file 5: Figure S2)
[18]. Distinct from these data, our 24-h data reveal a pre-
ponderance of genes involved in mitosis and the G2/M
transition (Additional file 5: Figure S2). Common to the 6 h
and 24 h data sets, and data from normal breast during the
luteal phase [17], is the upregulation of c-MYC, a progester-
one target gene, which likely accounts for many of the ef-
fects on the cell cycle genes that were observed (Additional
file 6: Figure S3). This is the subject of future experiments.
The transition into G2/M is governed by cyclin B/
CDK1 [26]; expression of both of these genes is in-
creased by R5020 binding to PR, and TPA significantly
decreases their expression. Also decreased is the expres-
sion of the cell division cycle 25C (CDC25C) and
CDC25B genes. The CDC25 proteins dephosphorylate
CDK1, which promotes the G2/M transition [26]. The
decrease in cyclin B1 and B2 RNA expression is likely
secondary to TPA’s disruption of progestin/PR-induced
classical transcriptional regulation of c-MYC expression
[27]. The association of ERα-PR on the promoter of
CCND1 and MYC drives the progestin (MPA)-induced
expression of these genes and cell proliferation [28].
There is abundant evidence that c-Myc binds to the
CDK1 promoter and that overexpression of c-MYC leads
to increased expression of CDK1 [29–31]. Therefore, it
is probable that TPA interferes with the PR transcrip-
tional activation of c-MYC resulting in a plethora of
downstream effects one of which is decreased CDK1 ex-
pression and no transit through G2/M. This is an hy-
pothesis to be tested.
Progesterone binding to membrane-proximal PR acti-
vates cytoplasmic kinases that participate in signaling
pathways that result in a number of post-translational
modifications of PR [5]. These receptor modifications
determine PR function by altering PR intracellular
localization and turnover, and the specific promoters to
which PR binds. PR-initiated rapid c-Src→MAPK sig-
naling stimulates feed-forward phosphorylation of PR-B
at serine 345, which tethers to Sp1 and increases the ex-
pression of both EGFR and p21 [32]. Our data reveal
that expression of both of these genes is significantly
downregulated by TPA, which suggests that the antipro-
gestin binding may interfere, perhaps by altering PR
conformation, with the phosphorylation of serine 345 or
with the binding to Sp1.
Beato and colleagues have studied how nucleosomal
organization and higher order chromatin structure influ-
ences the access of PR to its DNA binding sites [33]. An-
other of the consequences of activation of the c-SRC
tyrosine kinase pathway is the phosphorylation of PR and
Mitogen- and stress-activated protein kinase-1 (MSK1) by
Extracellular signal-regulated protein kinases 1 and 2
(ERK1/2). The resulting ternary complex, pPR/pERK/
pMSK1 is the active form of the receptor, which interacts
with chromatin targets in a subset of target genes [34].
We observe significant downregulation of MSK1 gene ex-
pression by TPA, which may limit the formation of the
ternary complex and therefore progesterone-mediated
gene expression.
The protein encoded by SMARCE1 (BAF57), a compo-
nent of the SWI/SNF chromatin remodeling complex,
plays an important role in ERα-mediated gene transcrip-
tion and estrogen-stimulated proliferation [35] as well as
being required for the response to androgen receptor
(AR) agonists [36, 37]. In contract to the critical role
BAF57 plays in regulating ER and AR function, tran-
scription is significantly decreased by the progesterone
agonist R5020 and increased by the addition of TPA to
R5020. In addition, IPA upstream analysis indicted
SMARCE1 activation in the TPA treated T47D cells
(Additional file 4: Table S5). Transfection of the breast
cancer cell line BT549 with BAF57 results in cell cycle
arrest and apoptosis [38]. This is another avenue for fur-
ther investigation to determine if the increase in
SMARCE1 (BAF57) following TPA treatment is respon-
sible for the apoptosis observed at 24 h.
The cell cycle genes homology region CHR is a motif
found in the promotors of many late cell cycle genes
that display maximal expression in G2 and M [22]. This
region is bound by the DREAM complex in G0 and early
G1, which represses expression of the late cell cycle
genes. In early S phase MMB binds to the CHR and later
in the cell cycle MMB recruits FOXM1, which results in
initiation of transcription of the late cell cycle genes.
Proteosomal degradation of B-MYB in G2 and M leads
to maximal expression of these genes through activation
by FOXM1-MuvB (LIN9, LIN37, LIN52, LIN54 and
RBBP4) [22]. Of these genes, only the expression of
FOXM1 is affected by TPA and it is likely that the
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decreased expression of many of the 16 genes in the
presence of TPA is due to the decreased binding of
FOXM1 to CHR. CHR sites are usually found close to
two to three CCAAT-box elements that bind the NFY
transcription factor to activate transcription [39]. 14 of
the 16 genes display the consensus biding sequence,
however there was no statistically different expression of
the NFY genes in the presence of TPA. Nonetheless, IPA
upstream analysis suggests inhibition NFY mediated ex-
pression. Other factors, such as E2Fs, cooperate with
NFY proteins to active transcription [39, 40]. The ex-
pression of E2F1 has been shown to be regulated by pro-
gestins [41] and, therefore, E2Fs are candidates for
further study of the regulation of the 16 genes.
Our translational application of these observations is
the development of predictive biomarkers, which is par-
ticularly challenging in the prevention setting. Preventive
interventions must be based on an understanding of
breast cancer risk and of how risk is transduced at the
molecular level. Clinical and mouse data, reviewed by
Ober and Edwards [42], indicate that the cell prolifera-
tive signaling pathways regulated by progesterone/PR
contribute to the initiation and development of breast
tumors. Based on epidemiologic data, Pike and col-
leagues proposed over three decades ago that an agent,
which increases mitotic activity, such as progestogens,
increases the probability of converting DNA damage (ex-
ogenous and endogenous) into mutations [9]. They esti-
mated that the combined effect of a 2-year delay in
menarche and a zero postmenopausal mitotic rate would
reduce breast cancer incidence in the US by 50 %. Our
data, which point to a significant effect of antiprogestins,
such as TPA, on mitosis (Fig. 5c,d) and transit through
the cell cycle, align nicely with this elegant preclinical
and epidemiologic work, supporting the potential effi-
cacy of these drugs in the prevention of breast cancer.
The development of antiprogestins as breast cancer pre-
vention agents requires the identification of biomarkers
that reflect effective abrogation of progesterone signal-
ing, particularly in pathways that are known to be in-
volved in the evolution of malignancy. A strength of our
approach is the comparison of genes with increased ex-
pression in T47D cells following R5020 administration
with those genes with increased expression in the nor-
mal breast during the luteal phase, thereby identifying a
gene set that predicts functional endogenous progester-
one signaling in human breast tissue in the presence of
endogenous estrogen. A subset of the initially identified
16 overlapping genes, AURKB, BUB1, CDC20, CDC25C,
CDCA3, CDK1, CCNA2, CCNB2 and TPX2, were vali-
dated in a separate, independent experiment in which
they had significantly increased expression in the pres-
ence of P4 and R5020 and significantly decreased ex-
pression when TPA was administered. These data enable
us to define a potential biomarker set for trials where
TPA is being tested for the prevention, and possibly the
therapy, of human breast cancer. We envision that the
expression of these genes could be assayed in high-risk
premalignant lesions thereby identifying both the lesions
whose growth is driven by progesterone signaling and
the patients who would potentially benefit from TPA
prevention. With regard to therapy, the ability of the genes
we have identified, individually or in combination, to se-
lect sensitive tumors is presently being tested in a preclin-
ical model; and will subsequently be tested in our ongoing
clinical trial. Recent data of Mohammad and colleagues
comparing the growth of MCF-7 xenograft tumors in the
presence of estrogen alone or estrogen plus progesterone
demonstrates decreased growth with the addition of pro-
gesterone [43]. This is similar to our data in Fig. 1g.
Whether the addition of TPA will result in additional re-
duced proliferation that also mirrors our in vitro data is
the purpose of our trial.
Conclusions
TPA administration to T47D cells results in a decrease in
cell proliferation at 24 h, which is maintained over time
only in the presence of estradiol. One possible mechanism
for this observed decrease is that TPA, by blocking pro-
gesterone signaling, decreases the expression of genes that
facilitate the G2/M transition resulting in fewer cells in
this phase of the cell cycle. Comparing genes induced by
the progestin R5020 in T47D cells with those increased in
the luteal-phase normal breast, we have identified a set of
genes that predict functional progesterone signaling in tis-
sue. This gene set may enable the identification of
progesterone-responsive lesions and, thereby the selection
of patients who will benefit from TPA utilized for the pre-
vention, and possibly the therapy, of human breast cancer.
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